Section 2. Section 58-37-7 is amended to read:58-37-7. Labeling and packaging controlled substance -- Informational pamphlet for opiates -- Naloxone education and offer to dispense.(1)A person licensed pursuant to this act may not distribute a controlled substance unless it is packaged and labeled in compliance with the requirements of Section 305 of the Federal Comprehensive Drug Abuse Prevention and Control Act of 1970.(2)No person except a pharmacist for the purpose of filling a prescription shall alter, deface, or remove any label affixed by the manufacturer.(3)Whenever a pharmacy sells or dispenses any controlled substance on a prescription issued by a practitioner, the pharmacy shall affix to the container in which the substance is sold or dispensed:(a)a label showing the:(i)pharmacy name and address;(ii)serial number; and(iii)date of initial filling;(b)the prescription number, the name of the patient, or if the patient is an animal, the name of the owner of the animal and the species of the animal;(c)the name of the practitioner by whom the prescription was written;(d)any directions stated on the prescription; and(e)any directions required by rules and regulations promulgated by the department.(4)Whenever a pharmacy sells or dispenses a Schedule II or Schedule III controlled substance that is an opiate, the pharmacy shall:(a)affix a warning to the container or the lid for the container in which the substance is sold or dispensed that contains the following text:(i)"Caution: Opioid. Risk of overdose and addiction"; or(ii)any other language that is approved by the Department of Health and Human Services;(b)beginning January 1, 2024:(i)offer to counsel the patient or the patient's representative on the use and availability of an opiate antagonist as defined in Section 26B-4-501; and(ii)offer to dispense an opiate antagonist as defined in Section 26B-4-501 to the patient or the patient's representative, under a prescription from a practitioner or under Section 26B-4-510, if the patient:(A)receives a single prescription for 50 morphine milligram equivalents or more per day, calculated in accordance with guidelines developed by the United States Centers for Disease Control and Prevention;(B)is being dispensed an opioid and the pharmacy dispensed a benzodiazepine to the patient in the previous 30 day period; or(C)is being dispensed a benzodiazepine and the pharmacy dispensed an opioid to the patient in the previous 30 day period.(5)(a)A pharmacy who sells or dispenses a Schedule II or Schedule III controlled substance that is an opiate shall, if available from the Department of Health and Human Services, print and prominently display at the point of sale the informational pamphlet developedcreated by the Department of Health and Human Services under Section 26B-4-514.(b)The board and the Department of Health and Human Services shall encourage pharmacies to use the informational pamphlet to engage in patient counseling regarding the risks associated with taking opiates.(c)The requirement in Subsection (5)(a) does not apply to a pharmacy if the pharmacy is unable to obtain the informational pamphlet from the Department of Health and Human Services for any reason.(6)A person may not alter the face or remove any label so long as any of the original contents remain.(7)(a)An individual to whom or for whose use any controlled substance has been prescribed, sold, or dispensed by a practitioner and the owner of any animal for which any controlled substance has been prescribed, sold, or dispensed by a veterinarian may lawfully possess it only in the container in which it was delivered to the individual by the person selling or dispensing it.(b)It is a defense to a prosecution under this subsection that the person being prosecuted produces in court a valid prescription for the controlled substance or the original container with the label attached.